Sumitomo Pharma America, Inc.
Profile
Sunovion is determined to help people breathe easy and sleep properly, among other things. The pharmaceutical company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its marketed products are asthma drug Xopenex, insomnia therapy Lunesta, schizophrenia treatment Latuda, and Brovana, a chronic obstructive pulmonary disease (COPD) treatment. Sunovion markets its products to primary care physicians and some specialists in the US. Sunovion is a subsidiary of Japanese firm Sumitomo Dainippon Pharma.
Sunovion is a global biopharmaceutical company whose spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. Sunovion’s vision is to lead the way to a healthier world. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments for people with serious psychiatric, neurological and respiratory conditions. For more information, visit Sunovion.com.